INVESTOR ALERT: Wolf Haldenstein Announces Class Action Lawsuit Against Sarepta Therapeutics, Inc. (NASDAQ: SRPT)

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly making false and misleading statements regarding its gene therapy product ELEVIDYS during the specified Class Period [1][2]. Allegations in the Complaint - Sarepta is accused of misrepresenting the safety of ELEVIDYS, despite serious risks associated with the product [7]. - The company allegedly failed to detect or disclose severe adverse events during clinical trials [7]. - It is claimed that Sarepta withheld material information that led to halted dosing, increased regulatory scrutiny, and suspension of shipments [7]. - The company is also said to have lacked a reasonable basis for positive statements about ELEVIDYS's safety and potential for expanded use [7]. Key Events and Stock Impact - Investors who purchased Sarepta securities during the Class Period and suffered losses have until August 25, 2025, to request the Court to appoint them as lead plaintiff [3].